William J.M et al found that upfront radiotherapy yield better outcomes for brain metastases in EGFR mutant NSCLC patients, the median OS in patients receiving upfront WBRT was 30 months, while the median OS was 25 months in those undergoing upfront EGFR-TKIs [30]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.